Lannett’s US Selexipag Chance Moved Back To 2030, Alembic Leads The Charge
US-Based Firm Deals Out Of Para IV Litigation Involving Two Uptravi Patents
Lannett will recognize the validity and enforceability of pair of US patents shielding the tablet formulation of J&J’s Uptravi (selexipag) blockbuster until 2030, under a consent judgment and order of permanent injunction signed by a judge in a federal district court in Delaware.
